Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
07/2005
07/05/2005CA2327439C Combination therapy for the treatment of tumors
07/05/2005CA2280875C Remedies for lymphocytic tumors
07/05/2005CA2215793C Use of neuronal apoptosis inhibitor protein (naip)
07/05/2005CA2129663C Biosynthetic binding protein for cancer marker
07/05/2005CA2123811C Type i and type ii surface antigens associated with staphylococcus epidermidis
07/05/2005CA2118928C Saponin-antigen conjugates and the use thereof
06/2005
06/30/2005WO2005059137A1 Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof
06/30/2005WO2005059136A2 Dna-sequence and recombinant production of group 4 major allergens from cereals
06/30/2005WO2005059123A2 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders
06/30/2005WO2005059122A1 Pathogenic bovine enterovirus, vaccines, and diagnostic methods
06/30/2005WO2005058967A2 Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
06/30/2005WO2005058963A1 Anti-hiv antibody
06/30/2005WO2005058961A2 Antibodies specific for human galanin, and uses thereof
06/30/2005WO2005058948A1 Lsa-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria
06/30/2005WO2005058941A2 Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
06/30/2005WO2005058940A2 Immunogenic peptide carrier conjugates and methods of producing same
06/30/2005WO2005058936A2 Dna sequence, and recombinant production of the grass pollen allergen lol p 4
06/30/2005WO2005058865A2 Assay for entactogens
06/30/2005WO2005058864A1 Assay for entactogens
06/30/2005WO2005058815A2 Ip-10 antibodies and their uses
06/30/2005WO2005058474A1 Cryogranulation and storage method for active pharmaceutical agents
06/30/2005WO2005058365A1 Pharmaceutical preparation containing an antibody for the egf receptor
06/30/2005WO2005058362A2 Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules
06/30/2005WO2005058359A2 Method for neutralizing effects of crp for increasing immune reactions to hiv
06/30/2005WO2005058357A1 Virus-like particle (vlp) as vaccine
06/30/2005WO2005058356A2 Methods for porducing storage stable viruses and immunogenic compositions thereof
06/30/2005WO2005058355A1 Immune stimulation by administration of bacteria
06/30/2005WO2005058354A1 Recombinant vibrio cholerae strain and vaccine comprising said strain
06/30/2005WO2005058353A1 Passive immunization against clostridium difficile disease
06/30/2005WO2005058352A2 Treatment of rheumatoid arthritis with galectin-3 antagonists
06/30/2005WO2005058351A2 Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers
06/30/2005WO2005058350A1 Novel vaccines for treating or preventing infections by echinococus parasites
06/30/2005WO2005058349A2 Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
06/30/2005WO2005058278A1 Drug delivery compositions and methods
06/30/2005WO2005058251A2 Hla-dr-specific antibodies, compositions and methods
06/30/2005WO2005058234A2 Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation
06/30/2005WO2005058006A2 Methods and compositions comprising bacteriophage nanoparticles
06/30/2005WO2005044989A3 Polynucleotides and polypeptides of anaplasma phagocytophilum and methods of using the same
06/30/2005WO2005044301A3 Use of specific histones for the treatment of parasitic diseases
06/30/2005WO2005042560A3 Non-viral delivery of compounds to mitochondria
06/30/2005WO2005042016A3 Stabilised compositions
06/30/2005WO2005040206A8 Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it
06/30/2005WO2005032475A3 In vivo efficacy of ny-eso-1 plus adjuvant
06/30/2005WO2005032343A3 Hedgehog signaling in prostate regeneration neoplasia and metastasis
06/30/2005WO2005025494A3 Vaccine immunotherapy for immune suppressed patients
06/30/2005WO2005017093A3 Polypeptides of streptococcus pyogenes
06/30/2005WO2005009369A3 A ca6 antigen-specific cytotoxic conjugate and methods of using the same
06/30/2005WO2005000881A3 Live attenuated viral vaccines for eastern equine encephalitis virus
06/30/2005WO2004110392A3 Compositions and methods for treating coronavirus infection and sars
06/30/2005WO2004103293A3 Modulators of the p2y10 receptor useful in altering t lymphocyte function
06/30/2005WO2004092210A3 Molecules having immunomodulatory activity
06/30/2005WO2004058178A3 Uses of mammalian cytokine; related reagents
06/30/2005WO2004018999A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
06/30/2005WO2004016643A3 Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
06/30/2005WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
06/30/2005WO2004001381A3 Novel raag10 cell surface target and a family of antibodies recognizing that target
06/30/2005WO2003018611A3 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
06/30/2005US20050144658 Test and model for Alzheimer's disease
06/30/2005US20050144109 Electronic trading data integration and protection system
06/30/2005US20050143569 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides
06/30/2005US20050143561 Lawsonia intracellularis proteins, and related methods and materials
06/30/2005US20050143308 Survivin, a protein that inhibits cellular apoptosis, and its modulation
06/30/2005US20050143307 Biological activity that prevents the binding of formyl methionine-leucine-phenylalanine (fMLP) and/or C5a protein to granulocytes; acute and chronic inflammation reactions and HIV infection
06/30/2005US20050143306 Antigenic peptide fragments of growth differentiation factor 8, and related immunogens, vaccines; Immunization; drug screening
06/30/2005US20050143284 Vaccination
06/30/2005US20050142641 antigens having altered antigenic profiles, uses in immunotherapy such as allergy vaccination and/or desensitization
06/30/2005US20050142640 MUC-1 derived peptides
06/30/2005US20050142635 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic
06/30/2005US20050142620 Compositions and methods for the therapy and diagnosis of lung cancer
06/30/2005US20050142615 Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection
06/30/2005US20050142604 Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210
06/30/2005US20050142566 Sperm-specific cation channel, catSper2, and uses therefor
06/30/2005US20050142557 Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
06/30/2005US20050142541 Antibodies for oncogenic strains of HPV and methods of their use
06/30/2005US20050142151 Live attenuated vaccines against brucellosis and infection by other diseases; trans complementation of the Brucella wboA gene is used to maintain an expression vector in an attenuated Brucella host cell in a vaccinee; heterologous antigens can be expressed using this Brucella platform
06/30/2005US20050142149 Virulence genes and proteins, and their use
06/30/2005US20050142148 e.g. include antigenic gene product of another virus, such as influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus; respiratory tract infections
06/30/2005US20050142146 Vaccine; against Chlamydia pneumonia; therapy, prevention of infections,
06/30/2005US20050142145 Derivatives of choline binding proteins for vaccines
06/30/2005US20050142144 Epitope sequences
06/30/2005US20050142143 Capable of accumulating in the endoplasmic reticulum; melanoma antigen; vaccines; treating melanoma
06/30/2005US20050142142 recombinant T cell receptor ligand (RTL) for use treating autoimmune diseases
06/30/2005US20050142139 and a histidine buffer; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection
06/30/2005US20050142138 Endothelial cell expression patterns
06/30/2005US20050142137 Human monoclonal antibodies against secretory leukocyte protease inhibitor (SLPI); host cells, expression vectors; anticancer agents
06/30/2005US20050142136 Anti-interleukin 8 therapy for tumor osteolysis
06/30/2005US20050142132 Prevention and treatment of amyloidogenic disease
06/30/2005US20050142120 Cells expressing anti-Fc receptor binding components
06/30/2005US20050142113 Pharmaceutical composition having a parasite with a chorismate synthase gene that is knocked out; for use against apicomplexan parasites which cause malaria, toxoplasmosis, sryptosporidiosis, and eimeriosis
06/30/2005US20050142108 Methods of modulating cytokine activity; related reagents
06/30/2005US20050142098 Polyoxyethylene glycol conjugated neublastin polypeptide dimers; exhibit prolonged bioavailability
06/30/2005US20050142069 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
06/30/2005DE10355904A1 Feste Formen von anti-EGFR-Antikörpern Solid forms of anti-EGFR antibodies
06/30/2005CA2560045A1 Methods and compositions comprising bacteriophage nanoparticles
06/30/2005CA2550893A1 Molecular signature of the pten tumor suppressor
06/30/2005CA2550155A1 Hla-dr-specific antibodies, compositions and methods
06/30/2005CA2550108A1 Active immunization against clostridium difficile disease
06/30/2005CA2549573A1 Dna sequence, and recombinant preparation of group 4 major allergens from cereals
06/30/2005CA2549552A1 A.beta. immunogenic peptide carrier conjugates and methods of producing same
06/30/2005CA2549303A1 Novel sodium channel
1 ... 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 ... 1823